A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group

Karschnia P, Young JS, Wijnenga MM, Sciortino T, Teske N, Corell A, Wagner A, Youssef G, Park YW, Häni L, Jünger ST, Dono A, Ehret F, Mireles EE, Neidert N, Bruno F, Tuchek CA, van der Vaart T, Rossi M, Nibali MC, Gay L, Gramelt A, Tandon N, Ahn SS, Chang JH, Weller M, Vincent AJ, Goldbrunner R, Cahill DP, Huang RY, Raabe A, Meyer B, Beck J, Molinaro AM, Chang SM, Vogelbaum MA, Rudà R, Vik-Mo EO, Dietrich J, Esquenazi Y, Grau SJ, Wen PY, Jakola AS, Schnell O, Bello L, van den Bent MJ, Hervey-Jumper S, Berger MS, Tonn JC (2025)

Publication Type: Journal article

Publication year: 2025

Journal

Book Volume: 26

Pages Range: 1638-1650

Journal Issue: 12

DOI: 10.1016/S1470-2045(25)00534-0

Abstract

Background The efficacy of resection in IDH -mutant grade 2 gliomas remain controversial since terminology for the extent of resection has been inconsistently applied across studies. We aimed to establish a standardised classification for the extent of resection and assess the association between supramaximal resection and survival across molecular subtypes. Methods In this international, multicentre, retrospective study, patients aged 18 years and older with newly diagnosed grade 2 IDH -mutant glioma were identified from institutional databases across 16 centres in the USA, Europe, and Asia between between Sept 1, 1993, and May 10, 2024. We used Cox proportional hazard regressions to analyse the associations between residual tumour and progression-free survival and overall survival. Patients were stratified according to a previously postulated classification system based on residual tumour volume. A cohort of patients from UCSF diagnosed between Feb 16, 1998, and Nov 14, 2017, was used for geographically and institutionally independent external validation. Findings We identified 1391 patients with newly diagnosed IDH -mutant grade 2 gliomas, with a median follow-up of 81 months (95% CI 78–85). 728 patients (379 with astrocytoma and 349 with oligodendroglioma) received no first-line treatment beyond surgery, allowing us to study the isolated effects of resection. Patients with maximal T2-fluid attenuated inversion recovery (T2-FLAIR) resection (class 2; 0–5 cm³ remnant) had superior progression-free and overall survival compared with submaximal T2-FLAIR resection (class 3; 5–25 cm³ remnant) or minimal T2-FLAIR resection (class 4; >25 cm³ remnant), with 10-year survival rates of 82% (95% CI 76–87) versus 75% (62–84) versus 48% (29–65; p<0·0001) and 5-year progression-free survival rates of 44% (38–50) versus 25% (16–34) versus 12% (4–24; p<0·0001), respectively. Resection beyond T2-FLAIR borders (class 1) provided survival benefits, with a 10-year survival rate of 98% (95% CI 92–99) and a 5-year progression-free survival rate of 83% (76–88) for supramaximal T2-FLAIR resection (class 1). Associations between survival and extensive resection were evident after 3 years in astrocytomas, whereas survival curves separated after 6–8 years in oligodendrogliomas. The prognostic relevance of the four-tier classification was conserved in multivariable analyses, in 625 patients receiving first-line chemotherapy or radiotherapy (with or without chemotherapy), and in the external UCSF cohort of 381 patients with IDH -mutant grade 2 gliomas. Interpretation The proposed RANO classification for extent of resection could serve as a tool for prognostic stratification. Although associations between survival and extensive surgery are evident sooner in patients with astrocytoma, supramaximal resection also translates into survival benefits for patients with oligodendrogliomas. Funding None.

Authors with CRIS profile

Involved external institutions

University of San Francisco (USF) United States (USA) (US) Erasmus University Medical Center (MC) Netherlands (NL) Università degli studi di Milano Italy (IT) Sahlgrenska University Hospital / Sahlgrenska Universitetssjukhuset Sweden (SE) Technische Universität München (TUM) Germany (DE) Harvard University United States (USA) (US) Yonsei University Health System (YUHS) Korea, Republic of (KR) Inselspital, Universitätsspital Bern Switzerland (CH) Universität zu Köln Germany (DE) University of Texas Health Science Center at Houston (UTHealth Houston) United States (USA) (US) Oslo University Hospital / Oslo Universitetssykehus Rikshospitalet Norway (NO) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) H. Lee Moffitt Cancer Center & Research Institute United States (USA) (US) Ludwig-Maximilians-Universität (LMU) Germany (DE) Universitätsklinikum Freiburg Germany (DE) Universitätsspital Zürich (USZ) Switzerland (CH)

How to cite

APA:

Karschnia, P., Young, J.S., Wijnenga, M.M., Sciortino, T., Teske, N., Corell, A.,... Tonn, J.C. (2025). A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group. Lancet Oncology, 26(12), 1638-1650. https://doi.org/10.1016/S1470-2045(25)00534-0

MLA:

Karschnia, Philipp, et al. "A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group." Lancet Oncology 26.12 (2025): 1638-1650.

BibTeX: Download